Evidence map›Paper›PMID 41013451›Full record

ArticleBMC medical imaging2025

Efficacy of PSMA PET/CT radiomics analysis for risk stratification in newly diagnosed prostate cancer: a multicenter study.

Esmail Jafari, Amin Zarei, Habibollah Dadgar, Ahmad Keshavarz, Hamid Abdollahi, Rezvan Samimi, Reyhaneh Manafi-Farid, GhasemAli Divband, Babak Nikkholgh, Babak Fallahi and 5 more

Abstract readMulticenter Study
In one paragraph

Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Esmail JafariThe Persian Gulf Nuclear Medicine Research Center, Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Amin ZareiThe Persian Gulf Nuclear Medicine Research Center, Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Habibollah DadgarCancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran.
Ahmad KeshavarzIoT and Signal Processing Research Group, ICT Research Institute, Faculty of Intelligent Systems Engineering and Data Science, Persian Gulf University, Bushehr, Iran.
Hamid AbdollahiDepartment of Radiology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Rezvan SamimiKhatam PET/CT Center, Tehran, Iran.
Reyhaneh Manafi-FaridResearch Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
GhasemAli DivbandKhatam PET/CT Center, Tehran, Iran.
Babak NikkholghKhatam PET/CT Center, Tehran, Iran.
Babak FallahiResearch Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
HamidReza AminiKhatam PET/CT Center, Tehran, Iran.
Hojjat AhmadzadehfarDepartment of Nuclear Medicine, Klinikum Westfalen, Dortmund, Germany.
Arman RahmimDepartment of Radiology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Farshad ZohrabiDepartment of Urology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran.
Majid AssadiThe Persian Gulf Nuclear Medicine Research Center, Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran. assadipoya@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate-specific membrane antigen (PSMA) PET/CT plays an increasing role in prostate cancer management. Radiomics analysis of PSMA PET/CT images may provide additional information for risk stratification. This study aimed to evaluate the performance of PSMA PET/CT radiomics analysis in differentiating between Gleason Grade Groups (GGG 1–3 vs. GGG 4–5) and predicting PSA levels (below vs. at or above 20 ng/ml) in patients with newly diagnosed prostate cancer.

methodsIn this multicenter study, patients with confirmed primary prostate cancer were enrolled who underwent [68Ga]Ga-PSMA PET/CT for staging. Inclusion criteria required intraprostatic lesions on PET and the International Society of Urological Pathology (ISUP) grade information. Three different segments were delineated including intraprostatic PSMA-avid lesions on PET, the whole prostate in PET, and the whole prostate in CT. Radiomic features (RFs) were extracted from all segments. Dimensionality reduction was achieved through principal component analysis (PCA) prior to model training on data from two centers (186 cases) with 10-fold cross-validation. Model performance was validated with external data set (57 cases) using various machine learning models including random forest, nearest centroid, support vector machine (SVM), calibrated classifier CV and logistic regression.

resultsIn this retrospective study, 243 patients with a median age of 69 (range: 46–89) were enrolled. For distinguishing GGG 1–3 from GGG 4–5, the nearest centroid classifier using radiomic features (RFs) from whole-prostate PET achieved the best performance in the internal test set, while the random forest classifier using RFs from PSMA-avid lesions in PET performed best in the external test set. However, when considering both internal and external test sets, a calibrated classifier CV using RFs from PSMA-avid PET data showed slightly improved overall performance. Regarding PSA level classification (< 20 ng/ml vs. ≥20 ng/ml), the nearest centroid classifier using RFs from the whole prostate in PET achieved the best performance in the internal test set. In the external test set, the highest performance was observed using RFs derived from the concatenation of PET and CT. Notably, when combining both internal and external test sets, the best performance was again achieved with RFs from the concatenated PET/CT data.

conclusionOur research suggests that [68Ga]Ga-PSMA PET/CT radiomic features, particularly features derived from intraprostatic PSMA-avid lesions, may provide valuable information for pre-biopsy risk stratification in newly diagnosed prostate cancer.

Indexed as

Glutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAntigens, SurfaceGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm GradingProstate-Specific AntigenRadiomicsRetrospective StudiesRisk AssessmentAntigens, SurfaceFOLH1 protein, humanGallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIProstate-Specific Antigen[68Ga]Ga-PSMAGleason scorePET/CTProstate cancerProstate-specific antigen (PSA)Radiomics

Identifiers

PMID41013451
PMCPMC12465446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.